AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia

RecruitingNAAges 20 Days - 1 YearAllNational Liver Institute, Egypt
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Infants with initial diagnosis of biliary atresia with biliary atresia score \> 23.927 will be allocated for Kasai porto-enterostomy with intra-operative cholangiogram reaching type 3 biliary atresia anatomy as a final diagnosis. Exclusion Criteria: * Major cardiac, renal, pulmonary, neurological malformations or illnesses. * Hemoglobinopathies, such as sickle cell anemia * Active systemic infection. * White blood cell count \> 20,000 cells/mm3. * Platelet count \< 40,000 cells/mm3 or โ‰ฅ 800,000 cells/mm3. * Purpura fulminans or unexplained vascular thrombotic conditions.
๐Ÿ’Š

What it tests

  • Granulocyte Colony-Stimulating Factor
๐Ÿ“

Where

1 site
National Liver Institute
Cairo, Egypt
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy